Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer

The expanded use of second-generation antiandrogens revolutionized the treatment landscape of progressed prostate cancer. However, resistances to these novel drugs are already the next obstacle to be solved. Various previous studies depicted an involvement of the enzyme AKR1C3 in the process of cast...

Full description

Bibliographic Details
Main Authors: Mona Kafka, Fabian Mayr, Veronika Temml, Gabriele Möller, Jerzy Adamski, Julia Höfer, Stefan Schwaiger, Isabel Heidegger, Barbara Matuszczak, Daniela Schuster, Helmut Klocker, Jasmin Bektic, Hermann Stuppner, Iris E. Eder
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
ARK1C3
enzalutamide resistance
prostate cancer
AR-V7
spheroid culture
cancer-associated fibroblasts (CAFs)
Online Access:https://www.mdpi.com/2072-6694/12/8/2092

Internet

https://www.mdpi.com/2072-6694/12/8/2092

Similar Items